Dbv Technologies Stock Today
| DBVT Stock | USD 23.25 2.26 10.77% |
PerformanceGood
| Odds Of DistressLow
|
DBV Technologies is selling for under 23.25 as of the 3rd of March 2026; that is 10.77 percent up since the beginning of the trading day. The stock's last reported lowest price was 21.17. DBV Technologies has less than a 9 % chance of experiencing financial distress in the next few years and had a good performance during the last 90 days. The performance scores are derived for the period starting the 3rd of December 2025 and ending today, the 3rd of March 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 22nd of October 2014 | Category Healthcare | Classification Health Care |
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France. DBV Technologies operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 54.96 M outstanding shares of which 1.23 M shares are currently shorted by private and institutional investors with about 2.66 trading days to cover. More on DBV Technologies
Moving together with DBV Stock
Moving against DBV Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
DBV Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsDBV Technologies can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand DBV Technologies' financial leverage. It provides some insight into what part of DBV Technologies' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DBV Technologies (DBVT) is traded on NASDAQ Exchange in USA and employs 117 people. DBV Technologies is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.15 B. DBV Technologies conducts business under Biotechnology sector and is part of Health Care industry. The entity has 54.96 M outstanding shares of which 1.23 M shares are currently shorted by private and institutional investors with about 2.66 trading days to cover.
DBV Technologies currently holds about 247.97 M in cash with (104.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.32.
Check DBV Technologies Probability Of Bankruptcy
Ownership AllocationDBV Technologies holds a total of 54.96 Million outstanding shares. 30% of DBV Technologies outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Thus, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the entity is less than the current market value, you may not be able to make money on it.
Check DBV Ownership Details
DBV Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Vestal Point Capital Lp | 2025-12-31 | 300 K | |
| Balyasny Asset Management Llc | 2025-12-31 | 235 K | |
| New York State Common Retirement Fund | 2025-12-31 | 223.2 K | |
| Boothbay Fund Management, Llc | 2025-12-31 | 163.4 K | |
| Polymer Capital Management (hk) Ltd | 2025-12-31 | 64.5 K | |
| Nan Fung Trinity (hk) Ltd | 2025-12-31 | 37.1 K | |
| Two Sigma Investments Llc | 2025-12-31 | 33.9 K | |
| Barclays Plc | 2025-09-30 | 30 K | |
| Engineers Gate Manager Lp | 2025-12-31 | 25 K | |
| Artisan Partners Limited Partnership | 2025-12-31 | 3.3 M | |
| Vivo Capital, Llc | 2025-12-31 | 2.5 M |
DBV Technologies Historical Income Statement
DBV Stock Against Markets
DBV Technologies Corporate Management
| Jonathan Neely | VP Relations | Profile | |
| PharmD D | Chief Officer | Profile | |
| Joseph Becker | VP Communications | Profile | |
| Sbastien Robitaille | Chief Officer | Profile | |
| Wence Agbotounou | Chief Clinical Trial Officer | Profile | |
| Caroline Daniere | Chief Staff | Profile |
Additional Tools for DBV Stock Analysis
When running DBV Technologies' price analysis, check to measure DBV Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DBV Technologies is operating at the current time. Most of DBV Technologies' value examination focuses on studying past and present price action to predict the probability of DBV Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DBV Technologies' price. Additionally, you may evaluate how the addition of DBV Technologies to your portfolios can decrease your overall portfolio volatility.